0.001
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aeolus Pharmaceuticals Inc (PK) | AOLS | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.001 | 0.001 | 0.00189 | 0.001 | 0.001 | 16:33:23 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.0009 | 0.0021 | 0.0012 | 57.14% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5 | 21,010 | $ 0.001318 | $ 28 | 58,541 | 0.0006 - 0.003 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:32:36 | 7,500 | $ 0.001 | USD |
Aeolus Pharmaceuticals (PK) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 152.09k | 152.09M | $ -3.56M | - | - | 53.78M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 3.11k | $ - | 0.00% | - | - |
Aeolus Pharmaceuticals (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AOLS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0019 | 0.0019 | 0.001 | 0.0011193 | 30,172 | -0.0009 | -47.37% |
| 1 Month | 0.002 | 0.002 | 0.0009 | 0.0010404 | 42,491 | -0.001 | -50.0% |
| 3 Months | 0.0013 | 0.0021 | 0.0008 | 0.0012948 | 87,209 | -0.0003 | -23.08% |
| 6 Months | 0.0016 | 0.0021 | 0.0008 | 0.001401 | 111,266 | -0.0006 | -37.5% |
| 1 Year | 0.002455 | 0.003 | 0.0006 | 0.0013703 | 134,540 | -0.00146 | -59.27% |
| 3 Years | 0.18 | 0.25 | 0.00045 | 0.0170814 | 124,629 | -0.179 | -99.44% |
| 5 Years | 0.26 | 0.50 | 0.00045 | 0.0549783 | 81,955 | -0.259 | -99.62% |
Aeolus Pharmaceuticals (PK) Description
| Aeolus is developing a portfolio of novel metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at www.aolsrx.com |
